Fresh analysis reveals that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who stop traditional diet and exercise programs.
Research printed in a prominent health publication demonstrates that while obese individuals frequently drop about a fifth of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying such medications need to be cognizant of the potential of fast weight regain when the treatment ends," warns expert Dr. Susan Jebb.
This pace of recovery suggests a reversion to pre-treatment mass within about one and a half years.
Comparing Treatments
The analysis, which examined dozens of trials involving thousands of patients, contrasted the results of the injectable medications with other pills.
The team emphasize that individuals who lose weight through diet and exercise usually see a more gradual weight regain—around 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Doctors believe the way of the drugs is key to understanding the heightened weight return.
These medications copy a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of the hormone concentrations far above than normal could lead to the body to produce less of its endogenous GLP-1, and may also diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making binge eating far more likely."
A Lifelong Issue?
Health authorities advise the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.
A number of clinicians say that, given the high risk of weight regain, the therapy should be considered ongoing.
This perspective is reinforced by pharmaceutical companies, who state that the findings "highlight the persistent character of obesity," similar to managing diseases like diabetes.
User Accounts
People who have stopped the medication explain a powerful return of appetite.
"I experienced a switch activating and I was suddenly ravenous," said one woman.
This challenge is worsened if users have not established permanent lifestyle or habit modifications during therapy.
Significant Adoption
Recent estimates indicate that millions of people in the UK have tried these injections in the last 12 months, with interest remaining high.
- Use is greater among women compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Finally, researchers stress that while the jabs are effective agents for shedding pounds, they are not a magic fix and long-term success likely depends on integrated behavioural support.
